STOCK WATCH

■ NOVACYT shares plunged to their lowest level in over two years after it warned of a sharp downturn in business.

The maker of Covid-19 tests reported revenues for the six months to the end of June were £16.5m, much lower than the £52.2m delivered the previous year. If the fall in demand for Covid-19 products continued, Novacyt predicted its revenues for the full year would be £25m, much lower than previous forecasts of £35m to £45m. Shares fell 25.7pc, or 38.2p, to 110.5p.